WS Management’s Sarepta Therapeutics SRPT Stock Holding History

WS Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,706	Closed	-$1.45M	–	73
2021 Q3	$1.45M	Sell	15,706 -9,779	-38%	-$753K	0.15%	60
2021 Q2	$1.98M	Hold	25,485	–	–	0.2%	60
2021 Q1	$1.9M	Sell	25,485 -3,791	-13%	-$350K	0.2%	53
2020 Q4	$4.99M	Hold	29,276	–	–	0.52%	32
2020 Q3	$4.11M	Sell	29,276 -12,000	-29%	-$1.82M	0.44%	40
2020 Q2	$6.62M	Sell	41,276 -18,726	-31%	-$2.55M	0.81%	30
2020 Q1	$5.87M	Hold	60,002	–	–	0.64%	36
2019 Q4	$7.74M	Sell	60,002 -7,000	-10%	-$707K	0.66%	29
2019 Q3	$5.05M	Sell	67,002 -21,199	-24%	-$2.5M	0.39%	41
2019 Q2	$13.4M	Sell	88,201 -16,716	-16%	-$2.03M	0.87%	26
2019 Q1	$12.5M	Sell	104,917 -4,445	-4%	-$571K	0.76%	28
2018 Q4	$11.9M	Buy	109,362 +24,362	+29%	+$3.05M	0.58%	37
2018 Q3	$13.7M	Hold	85,000	–	–	0.45%	40
2018 Q2	$11.2M	Buy	+85,000	New	+$8.02M	0.32%	46

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

WS Management's SRPT Position: Q4 2021 in Review

WS Management sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 15,706 shares — an estimated $1.45M sold.

WS Management first reported a position in SRPT in Q2 2018 and held it in 14 quarters. The position peaked at $13.7M in Q3 2018. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

WS Management reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
WS Management sold 15,706 Sarepta Therapeutics shares in Q4 2021, an estimated $1.45M.
WS Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 14 quarters.
WS Management's Sarepta Therapeutics position peaked at $13.7M in Q3 2018.
343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on WS Management's 13F filing for Q4 2021, filed 11 Feb 2022.